Critical reviews in oncology/hematology
Cure8 research brief
Why This Matters
Research linking ETBF to intestinal inflammation and colorectal cancer suggests better detection and targeted therapies for this microbe could eventually affect IBD management and cancer risk assessment.
Who Should Pay Attention
Researchers studying the microbiome, clinicians interested in IBD and colorectal cancer pathogenesis, and translational scientists developing diagnostics or targeted antimicrobials.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This is a structured review article outlining the biology of ETBF and its major virulence factor BFT, how ETBF may contribute to intestinal inflammation and tumor risk, and current technical limits in detecting ETBF in patients.
The authors discuss prospects for integrated multi-omics diagnostics and molecular tests, and review a range of experimental or emerging targeted therapeutic strategies aimed at ETBF.
The review is framed as a comprehensive theoretical foundation rather than reporting new clinical trial results; it synthesizes existing mechanistic and translational research and highlights areas needing more validation.
Keep In Mind
This entry is an academic review (abstract-level content provided). It summarizes existing studies and technical prospects but does not report new trial results; clinical applications discussed remain prospective and require further validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCritical reviews in oncology/hematology
AuthorsChunyu Wang, Lihao Shi, Guiyuan Jin +3 more
InstitutionDepartment of Gastroenterology, Affiliated Hospital of Jining Medical University, Jining 272029, China.
Study typeJournal article, review
Indexed viaPubMed
Source typeResearch paper
PublishedAug 25, 2026, 12:00 AM
Content availableJournal abstract
Conflict statement: Conflict of Interest All authors declare no competing interests.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Nanoparticle technologies in the diagnosis and therapy of gastrointestinal diseases: Progress, challenges, and future directions.
Nanoparticle technologies could eventually enable more targeted drug delivery and improved imaging for IBD and related GI diseases, which may lead to better diagnosis and less systemic side effects. However, translation...
Fucose metabolism as a central axis linking inflammation, immunity, and cancer in the gut.
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
Cell cycle dysregulation: a central hub in colitis-associated colorectal carcinogenesis.
The review connects molecular cell-cycle changes to the progression from chronic IBD to colorectal cancer, pointing to pathways and cell-cycle regulators that could become prevention or treatment targets for...